Research Atlas · source screening

Polymyxin B

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

2,260

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Polymyxin B"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Polymyxin B-loaded PVP-capped silver nanoparticles: A potent approach against multidrug-resistant bacteria.

   Biomater Adv · 2026 Nov · PMID 42287940 · DOI 10.1016/j.bioadv.2026.215011

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer.

   Pharmacotherapy · 2026 Oct · PMID 42736534 · DOI 10.1002/phar.70202

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Physics-informed LSTM neural network for personalized pharmacokinetic modeling of polymyxin B in critically Ill patients.

   Eur J Pharm Sci · 2026 Oct 1 · PMID 42463031 · DOI 10.1016/j.ejps.2026.107609

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Polymyxin B and the Pulmonary Peril: A Case Series of Acute Respiratory Failure.

   Case Rep Crit Care · 2026 · PMID 42774857 · DOI 10.1155/crcc/5569011

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Physiologically Based Pharmacokinetic Modeling of Inhaled Polymyxin B: From Rabbit Optimization to Human Predictions.

   Pharm Res · 2026 Sep 17 · PMID 42754780 · DOI 10.1007/s11095-026-04194-1

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Phenotype-guided polymyxin B haemoadsorption in abdominal septic shock: a 2015-2026 evidence synthesis and proposed clinical pathway.

   Shock · 2026 Sep 11 · PMID 42726100 · DOI 10.1097/SHK.0000000000002940

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Tobramycin-Peptide Nucleic Acids Synergize with Polymyxin B and Other Bioactive Compounds to Inhibit Growth of Gram-Negative Bacteria.

   ACS Infect Dis · 2026 Sep 11 · PMID 42725966 · DOI 10.1021/acsinfecdis.6c00322

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. In vivo targeted fluorescence imaging and magnetic resonance imaging of E. coli bacterial infection using polymyxin B-conjugated and polyacrylic acid-grafted GdEuO(3) nanoparticles.

   Chem Commun (Camb) · 2026 Sep 10 · PMID 42717750 · DOI 10.1039/d6cc03175g

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Codelivering Polymyxin B and Phage Using Thermosensitive Hydrogel for Treating Carbapenem-Resistant Acinetobacter baumannii-Mediated Wound Infections.

   ACS Omega · 2026 Sep 8 · PMID 42730227 · DOI 10.1021/acsomega.6c00358

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Biomarker-guided polymyxin B haemoadsorption in endotoxic septic shock.

    Nephrol Dial Transplant · 2026 Sep 4 · PMID 42695977 · DOI 10.1093/ndt/gfag205

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Weight-based polymyxin B dosing for mortality and nephrotoxicity: an exploratory dose-response study.

    J Antimicrob Chemother · 2026 Sep 1 · PMID 42757502 · DOI 10.1093/jac/dkag322

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Physiologically-based pharmacokinetic model to predict loading dose polymyxin B exposure in critically ill patients with sepsis.

    Front Pharmacol · 2026 · PMID 42745804 · DOI 10.3389/fphar.2026.1827712

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching-right-to-reply.

    J Antimicrob Chemother · 2026 Sep 1 · PMID 42708710 · DOI 10.1093/jac/dkag288

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. In vitro assessment of eravacycline and polymyxin B combination against carbapenem-resistant Klebsiella pneumoniae.

    J Glob Antimicrob Resist · 2026 Sep · PMID 42497909 · DOI 10.1016/j.jgar.2026.07.008

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Factors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinion.

    Eur J Drug Metab Pharmacokinet · 2026 Sep · PMID 42489755 · DOI 10.1007/s13318-026-01021-1

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. The intrinsic potential of IgY-polymyxin B nanocombinations for combating colistin-resistant Salmonella enterica serovar Typhimurium isolated from ready-to-cook chicken.

    Poult Sci · 2026 Sep · PMID 42284728 · DOI 10.1016/j.psj.2026.107188

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Host inflammation drives low-exposure nephrotoxicity in critically ill patients receiving polymyxin B: A prospective study.

    Int J Antimicrob Agents · 2026 Aug 27 · PMID 42660470 · DOI 10.1016/j.ijantimicag.2026.107980

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing.

    Front Pharmacol · 2026 · PMID 42712890 · DOI 10.3389/fphar.2026.1900585

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Polymyxin B-Associated Muscle Injury: A Case Report.

    Infect Drug Resist · 2026 · PMID 42670325 · DOI 10.2147/IDR.S626064

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Response to Letter to the Editor "Methodological Considerations on the Longitudinal Analysis of Polymyxin B‑Induced Kidney Injury" [Response to Letter].

    Drug Des Devel Ther · 2026 · PMID 42662481 · DOI 10.2147/DDDT.S642300

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Incidence and Clinical Outcomes of Circuit Clotting During Prolonged Polymyxin B Hemoperfusion in Patients With Septic Shock: A Post Hoc Analysis of a Prospective Cohort Study.

    Ther Apher Dial · 2026 Aug 17 · PMID 42608712 · DOI 10.1002/1744-9987.70210

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Systems-Level Phosphoproteomic and RPPA Profiling Reveals Stress and DNA Damage Signalling as Early Drivers of Polymyxin B Neurotoxicity.

    Mol Neurobiol · 2026 Aug 14 · PMID 42601573 · DOI 10.1007/s12035-026-06126-x

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Possible Clinical Effects of Polymyxin B-Immobilized Fiber Columns via Platelet-Derived Lipid Mediators: A Prospective Observational Study.

    Blood Purif · 2026 Aug 11 · PMID 42579639 · DOI 10.1159/000553006

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Comment on: comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching.

    J Antimicrob Chemother · 2026 Aug 4 · PMID 42663139 · DOI 10.1093/jac/dkag287

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Comparative Effectiveness of Colistin Sodium versus Polymyxin B Sulfate Against CR-GNB: A Retrospective Cohort Study.

    Infect Drug Resist · 2026 · PMID 42572787 · DOI 10.2147/IDR.S615698

    Source metadata only · evidence grade unassigned · scientific conclusions pending review